Equities Analysts Set Expectations for Chimerix Q4 Earnings

Chimerix, Inc. (NASDAQ:CMRX) – Research analysts at Wedbush reduced their Q4 2025 earnings per share (EPS) estimates for Chimerix in a report released on Tuesday, December 10th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will earn ($0.28) per share for the quarter, down from their previous estimate of $0.28. Wedbush has a “Outperform” rating and a $6.00 price target on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share. Wedbush also issued estimates for Chimerix’s FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.06) EPS and FY2028 earnings at $0.47 EPS.

Other research analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research note on Wednesday. StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, August 21st.

Chimerix Trading Up 0.3 %

NASDAQ:CMRX opened at $2.95 on Friday. The firm has a fifty day simple moving average of $1.07 and a 200 day simple moving average of $0.96. Chimerix has a 1-year low of $0.75 and a 1-year high of $3.39. The stock has a market capitalization of $265.32 million, a PE ratio of -3.14 and a beta of 1.02.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CMRX. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the last quarter. Valeo Financial Advisors LLC boosted its stake in Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 69,505 shares during the period. Finally, Marshall Wace LLP bought a new stake in Chimerix in the 2nd quarter valued at $137,000. Institutional investors and hedge funds own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.